Drugs in Dev. Neurology
Phase II/ Phase III
Spain 
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MIN-102 (leriglitazone) is Minoryx’s novel orally bioavailable and selective PPARγ agonist with a potential first-in-class and best-in-class profile for adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with leriglitazone demonstrated PPARg engagement in all patients within the target range required for efficacy as assessed by a biomarker (adiponectin).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : European Investment Bank
Deal Size : $29.0 million
Deal Type : Funding
Details : The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : European Investment Bank
Deal Size : $29.0 million
Deal Type : Funding
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Sperogenix Therapeutics
Deal Size : $78.0 million
Deal Type : Licensing Agreement
Details : Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Sperogenix Therapeutics
Deal Size : $78.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Perflutren,Immunoglobulin
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia
Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.
Product Name : Albutein
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Perflutren,Immunoglobulin
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
Details : MIN-102 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Adrenoleukodystrophy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Flebogamma
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Flebogamma is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Postpoliomyelitis Syndrome.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 27, 2014
Lead Product(s) : Flebogamma
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albumin
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Details : Albumin is a Other Large Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 22, 2012
Lead Product(s) : Albumin
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
